argenx’s Post

Are you attending EASD? Please reach out, I would love to discuss our patient access and engagement with your team and how our modeling can provide valuable insights into your protocol design and execution. #EASD #PatientEngagement #ProtocolDesign

Generalized pustular psoriasis (GPP) is a rare but debilitating inflammatory skin disease that can be life-threatening if left untreated. Learn how interleukin-36 signaling is involved in the pathogenesis of this disease and how ongoing research to inhibit that signal holds the potential to transform treatment: https://lnkd.in/g7TcaYhs

Is there an increased risk of venous thromboembolism (VTE) when using JAK inhibitors to treat inflammatory bowel disease? Find the complete answer on #ScholarsInMedicine’s FAQ page; then continue to learn more in Dr. Michael Chiorean's lecture, Small Molecules User's Guide in IBD! https://lnkd.in/drU75rgB

#Pemphigus, a rare group of blistering autoimmune diseases affecting the skin and mucous membranes, has seen significant advancements in treatment. Corticosteroids, the mainstay of treatment, can suppress the immune system. However, patients with uncontrolled pemphigus face risks from opportunistic infections. Studies before 2007 highlighted Rituximab's benefits for some patients with severe adverse effects from long-term steroid therapy. Despite its efficacy, access to Rituximab was limited until FDA approval in 2018. Now recognized as a first-line therapy, Rituxan offers new hope for pemphigus patients. #AutoimmuneDiseases #MedicalAdvancements https://lnkd.in/daYWdu9d

Another important milestone for Century Therapeutics, Inc today. I'm biased, but convinced iPSCs with Allo-Evasion(TM) editing have much to offer in autoimmune in addition to oncology: off-the-shelf availability, precision-editing with no viral insertions, homogeneous product, reasonable COGS, and ability to re-dose with and without lymphodepletion. Onwards and upwards! #ipsc #autoimmune #lupus

🔍FACT! In the past 5 years, Veristat has supported 350+ clinical trials and consulting projects for Rare Disease therapies. 📽️ Check out our latest video to learn more about our Full Service Rare Disease expertise and how we can help you advance your therapies for to approval and commercial success👇 https://bit.ly/42FqxYj #RareDiseases #RareDiseaseMonth #VeristatYoutube

Dapagliflozin and finerenone's additive effects on albuminuria in non-diabetic chronic kidney disease: an open-label, randomized clinical trial: https://lnkd.in/dGgk_4Ss #dapagliflozin #finerenone #CKD #albuminuria #CKJ

Exciting findings from EULAR 2024 Annual Meeting reveal that Canakinumab offers a groundbreaking treatment approach for systemic juvenile idiopathic arthritis (sJIA) patients. This study shows sustained disease control without glucocorticoids, with fever controlled after just one injection. Dr. Horneff's research paves the way for steroid-free management of sJIA. Read more for insights on this promising first-line monotherapy. #rheumatology #sJIA #Canakinum

Exploring Sulfasalazine Uses, Benefits, and Side Effects Sulfasalazine is primarily used to treat inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease. Additionally, it is used to manage rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Know in Details: https://lnkd.in/dypvF7n9 #sulfasalazine #ibd #crohns #colitis #arthritisawareness #rheumatoidarthritis #psoriaticarthritis #ankylosingspondylitis #treatment #medication #healthcareinnovation #inflammation #guthealthforlife

It's #WorldHypoPARADay, an important day for us at Amolyt! As a team, we are dedicated to supporting the HypoPARA community and advocating for patients living with #hypoparathyroidism (HPT), a rare endocrine disease. We remain committed to advancing our lead candidate in Phase 3 development, which is designed to address the key therapeutic goals of HPT: normal blood calcium levels, normal urinary calcium excretion, and balanced bone turnover. Learn more here: https://bit.ly/3RVQcca